Objective—To evaluate the use of piroxicam for the
treatment of oral squamous cell carcinoma in dogs.
Design—Prospective case series.
Animals—17 dogs with measurable oral squamous
Procedure—Dogs were treated with piroxicam at a
dosage of 0.3 mg/kg (0.14 mg/lb) of body weight, PO,
every 24 hours until progressive disease or unacceptable
signs of toxicosis developed or the dog died.
Results—One dog had a complete remission (maxillary
tumor), and 2 dogs had partial remissions (lingual
tumor and tonsillar tumor). An additional 5 dogs had
stable disease, including 1 with a maxillary tumor, 2
with mandibular tumors, and 2 with tonsillar tumors.
Variables associated with tumor response were not
identified. Median and mean times to failure for the 3
dogs that had a remission were 180 and 223 days,
respectively. Median and mean times to failure for the
5 dogs with stable disease were 102 and 223 days,
respectively. Time to failure was positively associated
with tumor response and negatively associated with
tumor size. One dog had mild adverse gastrointestinal
tract effects that resolved with the addition of misoprostol
to the treatment regimen.
Conclusions and Clinical Relevance—Results suggest
that piroxicam may be useful in the treatment of
dogs with oral squamous cell carcinoma; response
rate was similar to that reported for other cytotoxic
treatments. Larger-scale studies are warranted to
determine what role piroxicam may have, alone or in
combination with other treatments, for the treatment
of dogs with oral squamous cell carcinoma. (J Am Vet
Med Assoc 2001;218:1783–1786)